Hi Tyke
It was a progess report but can't 100% agree with the 'no news', the NR was just not the 'expected news'
EU expectations were set way too high. And, agreed, in these markets thats way bad news. The bears, vulture funds, paid bashers, and even longer termers wanting more at lower prices can talk the share price down. I see at SH they're doing a great job of this.
Its all part of market psychology. The pro paid basher is the best at this.
IMO, The second problem is that confidence has eroded surrounding cash, threat of more dilution and the risk of DMX demise. I hope Keeler and company will stop with the tight news blackouts and answer the "too many unanswered questions." I like the annual report, it give personality to the company. I hope they could communicate with mini annual report like correspondence through out the year. Build some confidence, eh.
I've seen both these same problems before with other companies. I vividly recall AMGEN like it was yesterday. Then more recently with BCH, ANP, QLT, BRA, HML. Similar peak and valley with struggling developmental biotechs.
I am not convinced yet that getting 4 out of 13 countries is fatal and somehow the business plan is in ruins to the point the patient is terminal.
FACTs
We will be selling Directly into a 130,881,777 market. Approx 12.5% of which are 65 years and older, or 16,360,222 prime candidates who may have a high probability of OA. That doesn't mean younger folks, soccer heros, rugger players don't get OA or the chronic ouch, too. But the numbers by age is a great indicator of what we can expect. I just hope these new countries do not have the strict marketing rules and drug plan that Britain has. Despite contrary opinions, I do see cross border shopping happening here. Word of mouth of course is the slow boat, but effective. Advertising prescription drugs, if permitted, will reach more people faster. Don't know what the conversion rate would be. Any one know what advertising was done with Vioxx and CeleBREX in Europe?
Fact also, Pennsaid is priced better than Vioxx and CeleBREX. Should save lives as well as money for the drug plans.
Population
UK 59,511,464
Italy 57,634,327
Austria 8,131,111
Finland 5,167,486
Luxembourg 437,389
-------------------------------------------
130,881,777
Germany 82,797,408
France 58,978,172
Spain 39,996,671
Netherlands 15,892,237
Greece 10,601,527
Belgium 10,241,506
Sweden 8,873,052
Switzerland 7,262,372
Denmark 5,336,394
Ireland 3,797,257
243,776,596 rest of Europe
WORLD SALES THROUGH RETAIL PHARMACIES*
---------------------------------------------------------------------------
(Twelve months to July 2001)
NORTH AMERICA $129.9billion, up 16%
United States $124.0billion, up 16%
Canada $5.9billion, up 16%
EUROPE (leading 5) $51.6billion, up 10%
Germany $14.7billion, up 9%
France $13.3billion, up 9%
Italy $9.2billion, up 12%
United Kingdom $9.0billion, up 7%
Spain $5.4billion, up 11%
JAPAN (including hospitals) $49.1billion, up 4%
LATIN AMERICA (leading 3) $13.3billion, up 3%
Mexico $5.3billion, up 17%
Brazil $4.6billion, down 8%
Argentina $3.4billion, down 2%
AUSTRALIA/NEW ZEALAND $2.9billion, up 16% |
